Onconase shows promise as treatment for mesothelioma, other cancers

18

Apr
2007

Pre-clinical studies reported at the annual meeting of the American Association of Cancer Research on April 16, 2007 show that the chemotherapy drug Onconase significantly inhibits tumor growth in non-small cell lung cancer and breast cancer. Onconase is also subject to an ongoing Phase IIIb study in malignant mesothelioma, a form of cancer linked to asbestos exposure. The makers of the drug are hopeful that it will prove to be an effective treatment for these forms of cancer in the future

email this post print this page permanent link

Related News

Baron & Budd, P.C.:
Since 1977, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With over 50 attorneys and offices in Texas, California, and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs’ bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos and injuries caused by other toxic substances and pharmaceuticals. The firm also represents water authorities seeking clean-up costs for drinking water contamination; securities investors and governmental entities defrauded by corporate wrongdoing; and consumers. For more information about Baron & Budd, call 800-222-2766 or contact us via our secure form.

 
Other Offices:
  • Baton Rouge, LA
  • Beverly Hills, CA
  • Austin, TX
Main Office:
3102 Oak Lawn Avenue, Suite 1100
Dallas, TX 75219
For nearly 30 years, the law firm of Baron & Budd, P.C. has fought to safeguard the rights of mesothelioma victims and their families. MesotheliomaNews.com is a public service of Baron & Budd, P.C.

© 2008, Baron & Budd, P.C.